3,6-bis-(4-amino-butyl)-piperazine-2,5-dione | 23409-32-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3,6-bis-(4-amino-butyl)-piperazine-2,5-dione
• 英文别名: 3,6-Bis-(4-amino-butyl)-piperazin-2,5-dion；3,6-Bis(4-aminobutyl)piperazine-2,5-dione
• CAS: 23409-32-7
• 化学式: C₁₂H₂₄N₄O₂
• 分子量: 256.348
• InChiKey: NUYHTXOPSQBZKC-UHFFFAOYSA-N

物化性质

• 沸点：
  551.5±35.0 °C(Predicted)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  110
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,6-bis-(4-amino-butyl)-piperazine-2,5-dione 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 丙酮 为溶剂， 反应 1.0h， 生成 3,4-bis(N-fumaryl-N-(n-butyl)amino)-2,5-diketopiperazine
  参考文献：
  名称：

  Methods for the synthesis of activated ethylfumarates and their use as intermediates

  摘要：

  揭示的实施例涉及改进的方法，用于合成活性富马酸中间体，并将其用于化学合成。揭示的实施例描述了活化富马酸酯的合成，包括那些来自激活基团的酯，例如：4-硝基苯基、二苯基磷酸酰叠氮化物、皮瓦酰氯、氯磺酰异氰酸酯、对硝基苯酚、MEF、三氟乙酰和氯等，例如，乙酰基富马酰氯和随后在原位使用活化酯。进一步的实施例描述了从未分离和未纯化的中间体改进合成取代氨基烷基二酮哌嗪，从而实现了更高的产量和反应器吞吐量。

  公开号：

  US20130289278A1
• 作为产物：
  描述：

  三氟乙酰赖氨酸 在 四磷十氧化物 、 水 、 sodium hydroxide 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 1.5h， 生成 3,6-bis-(4-amino-butyl)-piperazine-2,5-dione
  参考文献：
  名称：

  Azithromycin-loaded respirable microparticles for targeted pulmonary delivery for the treatment of pneumonia

  摘要：

  Pneumonia is a major contributor to infection-based hospitalizations and deaths in the United States. Antibiotics such as azithromycin (AZM), although effective at managing pneumonia, often suffer from off-target diffusion and poor bioavailability when administered orally or via intravenous injection. The formation of biofilms at the disease sites makes the treatment more complicated by protecting bacteria from antimicrobial agents and thus necessitating a much higher dosage of antibiotics to eradicate the biofilms. As such, targeted pulmonary delivery of antibiotics has emerged as a promising alternative by providing direct access to the lung while also allowing higher local therapeutic concentrations but minimal systemic exposure. In this study, AZM was encapsulated in N-fumaroylated diketopiperazine (FDKP) microparticles for efficient pulmonary delivery. Both in vitro and in vivo results demonstrated that AZM@FDKP-MPs administered via intratracheal insufflation achieved at least a 3.4 times higher local concentration and prolonged retention times compared to intravenous injection and oral administration, suggesting their potential to better manage bacterial pneumonia. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.biomaterials.2018.01.022

文献信息

• [EN] POLYAMINE-FATTY ACID DERIVED LIPIDOIDS AND USES THEREOF<br/>[FR] LIPIDOÏDES DÉRIVÉS DE POLYAMINE-ACIDE GRAS ET LEURS UTILISATIONS
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2016004202A1

  公开（公告）日：2016-01-07

  The present disclosure provides polyamine-fatty acid derived lipidoids (e.g., compounds of Formula (I) or (II)) and methods of preparing the lipidoids. A described lipidoid includes R-C(=0)-0- moieties (where R is a lipid moiety), which may be hydrolyzed into non-toxic fatty acids. Also provided are compositions including a described lipidoid and an agent (e.g., polynucleotide, small molecule, peptide, or protein). The present disclosure also provides methods, kits, and uses that involve the lipidoids or compositions for delivering an agent to a subject, tissue, or cell and/or for treating and/or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases, respiratory diseases, painful conditions, psychiatric disorders, and metabolic disorders.

  本公开提供了聚胺脂肪酸衍生的脂质体（例如，化合物的化学式（I）或（II））以及制备脂质体的方法。所述脂质体包括R-C(=0)-0-基团（其中R是脂质基团），可以水解为无毒脂肪酸。还提供了包括所述脂质体和药剂（例如，多核苷酸、小分子、肽或蛋白质）的组合物。本公开还提供了涉及脂质体或组合物用于将药剂传递给受体、组织或细胞和/或用于治疗和/或预防一系列疾病的方法、试剂盒和用途，例如遗传疾病、增殖性疾病、血液疾病、神经系统疾病、免疫系统疾病、胃肠道疾病、呼吸系统疾病、疼痛症状、精神障碍和代谢性疾病。
• Pulmonary delivery of inhibitors of phosphodiesterase type 5
  申请人：Cheatham Wendell Wayman

  公开号：US20060099269A1

  公开（公告）日：2006-05-11

  Provided herein are compositions of 1) diketopiperazine salts of PDE5 inhibitors, and 2) DKP microparticles having a PDE5 inhibitors thereon, as well as methods for the pulmonary delivery of these compositions for the treatment of pulmonary hypertension and sexual dysfunction(s).

  本文提供了1）磷酸二酮肽盐的PDE5抑制剂组合物，以及2）DKP微粒具有PDE5抑制剂，以及用于将这些组合物经肺部递送以治疗肺动脉高压和性功能障碍的方法。
• [EN] ALKENYL SUBSTITUTED 2,5-PIPERAZINEDIONES AND THEIR USE IN COMPOSITIONS FOR DELIVERING AN AGENT TO A SUBJECT OR CELL<br/>[FR] 2,5-PIPÉRAZINEDIONES SUBSTITUÉES PAR UN ALCÉNYLE, ET LEUR UTILISATION DANS DES COMPOSITIONS DESTINÉES À L'ADMINISTRATION D'UN AGENT À UN SUJET OU UNE CELLULE
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2016205691A1

  公开（公告）日：2016-12-22

  Provided herein are compounds of Formula (I), and salts thereof, wherein each instance of RL is independently optionally substituted C6-C40 alkenyl. Further provided are compositions comprising a compound of Formula (I) and an agent. Further provided are methods and kits using the compositions for delivering an agent to a subject or cell and for treating and/or preventing a range of diseases. Further provided are methods of preparing compounds of Formula (I) and precursors thereof.

  本文提供了化合物的结构式（I）及其盐，其中RL的每个实例都是独立的、可选地取代的C6-C40烯基。此外，还提供了包含结构式（I）化合物和药剂的组合物。还提供了使用这些组合物将药剂传递给受试者或细胞，并用于治疗和/或预防一系列疾病的方法和试剂盒。还提供了制备结构式（I）化合物及其前体的方法。
• Compounds for protein stabilization and methods for their use
  申请人：Medtronic MiniMed, Inc.

  公开号：US20040171518A1

  公开（公告）日：2004-09-02

  The present invention is directed to stabilized polypeptide compositions. Typical embodiments of the present invention provide improved methods and materials for maintaining the stability of insulin polypeptide formulations. In particular, the disclosure provided herein teaches that the aggregation of insulin polypeptides can be inhibited by combining them with a class of compounds having the general formula A 1 —L 1 —S—L 2 —A 2 , wherein S comprises from one to seven consecutive atoms selected from the group consisting of nitrogen, carbon, and oxygen, wherein at least one of the atoms is a carbon atom; L 1 and L 2 are linking groups having from two to twelve atoms selected from the group consisting of nitrogen, carbon, oxygen, sulfur, and phosphorus; and A 1 and A 2 are carboxylic acid groups.

  本发明涉及稳定的多肽组合物。本发明的典型实施例提供了改进的方法和材料，用于维持胰岛素多肽制剂的稳定性。特别是，本文所提供的披露教导了通过将胰岛素多肽与一类具有一般式A1—L1—S—L2—A2的化合物结合来抑制胰岛素多肽的聚集，其中S由选择自氮、碳和氧的一到七个连续原子组成，其中至少有一个原子是碳原子；L1和L2是由选择自氮、碳、氧、硫和磷的两到十二个原子组成的连接基团；A1和A2是羧酸基团。
• Method and Composition for Treating Migraines
  申请人：Leone-Bay Andrea

  公开号：US20120071510A1

  公开（公告）日：2012-03-22

  A method for treating migraines is disclosed. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent, including small molecules and peptides being administered to a patient in need of treatment. In particular, the drug delivery system is designed for inhalation for delivery of drugs to the pulmonary circulation in a rapid and therapeutically effective manner.

  本发明公开了一种治疗偏头痛的方法。该方法利用快速药物输送系统，防止活性剂（包括小分子和肽）在治疗需要的患者中被失活或降解。特别地，该药物输送系统是为吸入而设计的，以快速和治疗有效的方式将药物输送到肺循环中。